Since 2018, checkpoint inhibitors (targeting PD-1 and its ligand PD-L1) have been approved by the Food and Drug Administration for the treatment of advanced MCC and show impressive clinical results, albeit not all patients respond to this treatment (Kaufman et al., 2016; Nghiem et al., 2016). Here, PDCD1 is linked to Merkel cell skin cancer.